Brexpiprazole

Details:

Brexpiprazole also called OPC-34712) is a novel D2 dopamine partial agonist investigational product currently in clinical trials for the treatment of depression, schizophrenia, and attention deficit hyperactivity disorder (ADHD).[1]Although it failed Stage 2 trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).

Biological Activity of Brexpiprazole

Brexpiprazole is a novel D2 dopamine partial agonist.
IC50 Value: N/A
Target: Dopamine Receptor
in vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. Similarly to aripiprazole, brexpiprazole exhibits partial agonism of D2R and an enhanced affinity for specific serotonin receptors (e.g., 5-HT1A, 5-HT2A and 5-HT7). Currently
in vivo: Brexpiprazole is in Phase III clinical trials for patients with schizophrenia and as adjunctive therapy for patients with major depressive disorder

Product Name: Brexpiprazole

CAS Number：913611-97-9

Appearance：White solid

Assay：98～102%

Packing：5g;10g;25g;50g;100g;1kg

Usage： Brexpiprazole is a novel D2 dopamine partial agonist.

Biological Activity of Brexpiprazole

Brexpiprazole is a novel D2 dopamine partial agonist.
IC50 Value: N/A
Target: Dopamine Receptor
in vitro: Brexpiprazole (OPC-34712) is a close structural analog of aripiprazole and shares some of its pharmacological properties. Similarly to aripiprazole, brexpiprazole exhibits partial agonism of D2R and an enhanced affinity for specific serotonin receptors (e.g., 5-HT1A, 5-HT2A and 5-HT7). Currently 
in vivo: Brexpiprazole is in Phase III clinical trials for patients with schizophrenia and as adjunctive therapy for patients with major depressive disorder